Skip to main content
Canada’s most-awarded newsroom for a reason
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
Canada’s most-awarded newsroom for a reason
$1.99
per week
for 24 weeks
// //

Numinus Wellness Inc TSX Venture: NUMI-X

Today's Change
Volume
Real-Time Last Update TSX Venture Last Sale

Today's Trading

Day Low 0.720
Day High 0.770
Open:0.730
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Numinus Wellness Inc is engaged in the business of providing integrated health services. The company's operating segments include Salvation Botanicals and Numinus Health. It generates maximum revenue from the Salvation Botanicals segment. Salvation Botanicals segment provides analytical services which include conducting independent analytical services, full spectrum testing and consulting, and developing proprietary methods and protocols to ensure accuracy and reliability using customized equipment.

Fundamentals

Market Capitalization, $K
Shares Outstanding, K
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

No rating

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

Latest Press Releases

Rising Acceptance For Treating Mental Disorders is Fueling Strong Growth in Psychedelic Drugs Market - Financial News Media
- MENAFN - Thu Oct 14, 2:51PM CDT
MENAFN - CMTX
Thu Oct 14, 2:51PM CDT
Palm Beach, FL -October 14, 2021 – FinancialNewsMedia.com News Commentary – Mental disorders are an urgent health crisis worldwide, especially exacerbated by COVID-19. As per a study by Harvard, the medical cost of mental health conditions is estimated to rise to $6 trillion by 2030. The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept pace, precipitating a crisis in psychiatric medicine. A novel innovation is psychedelic drug-assisted psychotherapy – the medically approved use of MDMA, psilocybin, and LSD as a component of elevated psychotherapy programs. According to a report from Research And Markets the psychedelic drugs market is expected to grow at a robust rate of 14.5% CAGR during the forecast period and reach a value of $6330 Mn in 2026 from $3210 in 2021 as there is a large unmet need for treatment driving the adoption of psychedelic drugs. Some key insights of the report were:"Ketamine eyes CAGR of 16.0% amongst all products in terms of value as it has a robust clinical trials portfolio in multiple diseases viz. depression (MDD, TRD), bi-polar disorder, suicidal ideation, drug and alcohol dependence, and social anxiety; Products with natural origin are anticipated to gain 90 BPS in terms of value market share by the end of the forecast period. Active Biotechs in the markets today include: . (NASDAQ: KTTA), (NASDAQ: SEEL), (NASDAQ: MNMD), (OTCPK: LKYSF) (TSXV: NUMI), (OTCPK: MYCOF) (NEO: MYCO).
Rising Acceptance For Treating Mental Disorders is Fueling Strong Growth in Psychedelic Drugs Market
- PR Newswire - PRF - Thu Oct 14, 7:45AM CDT
PR Newswire - PRF - CMTX
Thu Oct 14, 7:45AM CDT
PALM BEACH,  Fla., /PRNewswire/ -- Mental disorders are an urgent health crisis worldwide, especially exacerbated by COVID-19. As per a study by , the medical cost of mental health conditions is estimated to rise to by 2030. The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept pace, precipitating a crisis in psychiatric medicine. A novel innovation is psychedelic drug-assisted psychotherapy - the medically approved use of MDMA, psilocybin, and LSD as a component of elevated psychotherapy programs. According to a from Research And Markets the psychedelic drugs market is expected to grow at a robust rate of 14.5% CAGR during the forecast period and reach a value of in 2026 from in 2021 as there is a large unmet need for treatment driving the adoption of psychedelic drugs.  Some key insights of the report were: "Ketamine eyes CAGR of 16.0% amongst all products in terms of value as it has a robust clinical trials portfolio in multiple diseases viz. depression (MDD, TRD), bi-polar disorder, suicidal ideation, drug and alcohol dependence, and social anxiety; Products with natural origin are anticipated to gain 90 BPS in terms of value market share by the end of the forecast period.  Active Biotechs in the markets today include:  . (NASDAQ: KTTA), (NASDAQ: SEEL), (NASDAQ: MNMD), (OTCPK: LKYSF) (TSXV: NUMI), (OTCPK: MYCOF) (NEO: MYCO).
Numinus Upgrades Psychedelics Lab to Increase Research Service Capabilities
- CNW Group - Fri Oct 8, 8:00AM CDT
CNW Group - CMTX
Fri Oct 8, 8:00AM CDT
COMTEX_394789459/2669/2021-10-08T09:00:34
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 0.660 +9.09% increase
on 10/13/21
Period Open:0.770
Price movement based on the high, low and last over the given period.
0.850 -15.29% decrease
on 09/22/21
-0.050 (-6.49%) decrease
since 09/17/21
3-Month 0.660 +9.09% increase
on 10/13/21
Period Open:1.050
Price movement based on the high, low and last over the given period.
1.090 -33.94% decrease
on 07/19/21
-0.330 (-31.43%) decrease
since 07/16/21
52-Week 0.335 +114.93% increase
on 10/19/20
Period Open:0.335
Price movement based on the high, low and last over the given period.
2.450 -70.61% decrease
on 12/15/20
+0.385 (+114.93%) increase
since 10/16/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies